Cargando…
Therapeutic and Adverse Effect of Anti-PD1 Immunotherapy in Melanoma: A Retrospective, Single-Institute Study of 222 Patients
SIMPLE SUMMARY: The introduction of checkpoint inhibitors, such as anti-PD1 and anti-CTLA4 approaches, resulted in a breakthrough step in the outcome of advanced melanoma. However, next to the improved efficacy, a wide range of side effects appeared. During our analysis, we explored the effects and...
Autores principales: | Eikenes, Grethe, Liszkay, Gabriella, Balatoni, Tímea, Czirbesz, Kata, Hunyadi, Karen, Kozéki, Zsófia, Kispál, Mihály Tamás, Baranyai, Fanni, Danyi, Tímea, Bőcs, Katalin, Kenessey, István |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417734/ https://www.ncbi.nlm.nih.gov/pubmed/37568785 http://dx.doi.org/10.3390/cancers15153966 |
Ejemplares similares
-
The Role of Stereotactic Radiotherapy in the Management of Melanoma, A Retrospective Single Institute Preliminary Study of 30 Patients
por: Kispál, Mihály, et al.
Publicado: (2022) -
Atezolizumab for the treatment of advanced recurrent basal cell carcinoma and urothelial carcinoma of bladder: a case report
por: Küronya, Zsófia, et al.
Publicado: (2022) -
Predictive and Prognostic Value of BRAF and NRAS Mutation of 159 Sentinel Lymph Node Cases in Melanoma—A Retrospective Single-Institute Study
por: Liszkay, Gabriella, et al.
Publicado: (2021) -
HLA Class I Downregulation in Progressing Metastases of Melanoma Patients Treated With Ipilimumab
por: Ladányi, Andrea, et al.
Publicado: (2022) -
“Immune B Cells know it better”: tumorimmunological panel assay to define tumor-associated antigen binding antibodies in patients with metastatic melanomas
por: Kotlan, Beatrix, et al.
Publicado: (2015)